Studies from Cardinal Health Yield New Data on Rheumatoid Arthritis (Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid...).

A report from Cardinal Health discusses the use of abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis. The study found that patients treated with abatacept showed improved clinical outcomes and remission rates at all time points. The research provides real-world evidence supporting the use of abatacept in this patient population. For more information, the full article can be accessed for free at the Journal of Comparative Effectiveness Research website. [Extracted from the article]